Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of Traws Pharma, Inc. common stock. They disclose beneficial ownership of 1,555,423 shares of common stock, representing 9.5% of the class, held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.
The position includes 1,077,281 shares issuable upon exercise of warrants that are exercisable within 60 days, subject to a 9.99% beneficial ownership limitation. The 9.5% ownership figure is based on 16,445,558 shares outstanding, which includes the warrant shares and 15,368,277 shares outstanding as of August 12, 2026. The reporting persons emphasize that their filing does not constitute an admission of beneficial ownership or group status under the Exchange Act.
Traws Pharma, Inc. reported no revenue for the three and six months ended June 30, 2026, down from $2.7 million and $2.8 million in the prior-year periods after termination of a Symbio license. The company recorded a six‑month net loss of $10.2 million versus prior‑year net income driven by a large 2025 warrant revaluation gain. Cash and cash equivalents were $5.0 million with total assets of $11.5 million and an accumulated deficit of $650.1 million.
Research and development expenses rose to $6.0 million for the first half of 2026, reflecting higher virology spending on tivoxavir marboxil and ratutrelvir, while general and administrative costs increased to $5.5 million, largely from higher professional fees and stock‑based compensation. A $1.4 million legacy R&D accrual reversal reduced operating expenses. Management states that current cash will not fund operations for 12 months, and explicitly notes substantial doubt about the ability to continue as a going concern.
Liquidity was supported by an April 2026 private placement providing $10.0 million in gross proceeds (about $9.4 million net) and ATM sales adding $2.0 million. New April 2026 warrants could provide up to $50.0 million in additional gross proceeds if fully exercised for cash. Clinically, ratutrelvir showed favorable Phase 2 COVID‑19 results, but tivoxavir marboxil faces an MHRA deferral for a human challenge study and a U.S. FDA clinical hold. Traws also received a Nasdaq notice for failing the $1.00 minimum bid price requirement.
Traws Pharma, Inc. reported Q2 2026 results, highlighting continued investment in its antiviral pipeline and a more constrained balance sheet. For the quarter ended June 30, 2026, the company generated no revenue versus $2.7 million a year earlier, reflecting the absence of prior-period deferred revenue tied to a terminated oncology license. It reported a net loss of $3.1 million, or $0.16 per basic and diluted share, compared with a $0.9 million loss, or $0.11 per share, in Q2 2025.
For the first half of 2026, Traws recorded a net loss of $10.2 million, versus net income of $20.6 million in the first half of 2025, when results included a $26.7 million non-cash gain from changes in warrant liabilities. As of June 30, 2026, cash and cash equivalents were $5.0 million, up from $3.8 million at year-end, and total stockholders’ equity was $1.7 million versus a deficit of $0.6 million at December 31, 2025. Management expects existing cash plus anticipated at-the-market equity proceeds to fund operations into the first quarter of 2027, but indicates additional financing may be required thereafter.
Operationally, the company is advancing tivoxavir marboxil (TXM), an oral prophylactic candidate for seasonal and pandemic influenza, and working to address regulatory feedback. It plans to resubmit an updated toxicology package to the UK MHRA by the end of Q3 2026 to enable a Phase 2a human influenza challenge study at hVIVO, while also preparing a comprehensive response to resolve the FDA clinical hold on the US IND with a goal of advancing the program in the United States by the end of 2026. In April 2026, Traws closed a financing providing $10.0 million upfront and potential access to up to $50.0 million through milestone-based warrant tranches linked to MHRA approval and challenge-study data.
Traws Pharma, Inc. received an amended Schedule 13G filing (Amendment No. 4) from Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank. The group now reports beneficial ownership of 0 shares of Traws Pharma common stock, representing 0% of the class.
The filing states that each reporting person has no sole or shared voting power and no sole or shared dispositive power over any shares of Traws Pharma common stock, confirming that they collectively own 5 percent or less of the class.
Traws Pharma, Inc. received a disclosure that Sirenia Capital Management LP and Alex Silverstein are reporting beneficial ownership in its common stock through warrants. The Sirenia-managed funds hold Reported Warrants exercisable for 6,565,474 shares of common stock, based on 15,150,669 shares outstanding as of May 18, 2026. The warrants are subject to a 9.99% Blocker, which prevents exercises that would take the Reporting Persons above 9.9% of the outstanding common stock. As a result, they currently cannot exercise all of the Reported Warrants and their actual beneficial ownership is less than the full 6,565,474 shares issuable upon full exercise.
Adage Capital Management, L.P. and affiliates reported their ownership in Traws Pharma, Inc. common stock. The group, consisting of Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 730,000 shares of Traws Pharma common stock.
This position represents 4.79% of the outstanding common stock, based on 15,228,328 shares outstanding as of June 30, 2026, as referenced from a company prospectus. The shares are held through Adage Capital Partners, L.P., with the reporting persons having shared voting and dispositive power over 730,000 shares and no sole voting or dispositive power. The reporting group states that they now hold 5 percent or less of the class, and they include customary language that the filing should not itself be construed as an admission of beneficial ownership beyond what is reported.
Traws Pharma, Inc. reported that on July 29, 2026 it received a notification letter from the Nasdaq Listing Qualifications Department stating that its common stock is not in compliance with the Nasdaq Capital Market minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price has been below $1.00 per share for at least 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing.
Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance, which requires a closing bid price at or above $1.00 per share for at least 10 consecutive business days, a period Nasdaq may extend to up to 20 days. If compliance is not regained, Nasdaq may grant a second 180‑day grace period if other listing standards are met and the company plans to cure the deficiency. Otherwise, the stock may be subject to delisting, which the company could appeal. Traws Pharma states it will monitor its bid price and consider options, but there is no assurance of regaining compliance.
Traws Pharma, Inc. reported a compensation-related insider transaction for Chief Science Officer Virology Charles David Pauza. He received a grant of 97,000 stock options on July 9, 2026, with an exercise price of $0.68 per share, vesting 100% on July 9, 2027 and expiring July 9, 2036. Following the award, he directly holds options for 97,000 underlying shares of common stock.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options to acquire 14,150 shares of common stock at an exercise price of $0.68 per share. The options, granted on July 9, 2026 under the 2021 Incentive Compensation Plan, vest 100% after one year and expire on July 9, 2036, leaving him holding options for 14,150 shares directly.
Traws Pharma, Inc. reported that Chief Operating Officer Nikolay Savchuk received a grant of stock options covering 93,000 shares of common stock on July 9, 2026. The options have an exercise price of $0.68 per share, expire on July 9, 2036, and vest 100% on the first anniversary of the grant date.